Clinical and Genetic Characteristics of Coronaviruses with Particular Emphasis on SARS-CoV-2 Virus
Joanna Iwanicka
Department of Biochemistry and Medical Genetics, School of Health Sciences in Katowice, Medical University of SilesiaKatowice, Poland
Orcid-ProfilSuche nach diesem Autor auf
, , und 19. Juni 2022
Über diesen Artikel
Artikel-Kategorie: Minireview
Online veröffentlicht: 19. Juni 2022
Seitenbereich: 141 - 159
Eingereicht: 09. Dez. 2021
Akzeptiert: 10. Apr. 2022
DOI: https://doi.org/10.33073/pjm-2022-022
Schlüsselwörter
© 2022 Joanna Iwanicka et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Brief characteristics of COVID-19 vaccines registered in the European Union_
| Vaccine | Platform | population Target | Vaccination schedule | Side effects | Effectiveness in registration trials |
|---|---|---|---|---|---|
| Comirnaty | mRNA | above 12 years old | 2 doses (second 3 weeks after first); booster dose 6 months after second | local side effects, flulike symptoms, myocarditis, pericarditis, erythema multiforme | 91.3–95.0% |
| Spikevax | mRNA | above 12 years old old | 2 doses (second 28 days after first); booster dose 6 months after second | local side effects, flulike symptoms, myocarditis, pericarditis, erythema multiforme | 94.1% |
| COVID-19 Vaccine Janssen | vector (adenoviral) | above 18 years old old | 1 dose, booster dose after 2 months | local side effects, flulike symptoms, thrombosis, thrombocytopenia, VITT, CLS, Guillain-Barre syndrome | 66.1–85.4% |
| Vaxzevria | vector (adenoviral) | above 18 years old | 2 doses, the second 4 to 12 weeks after the first | local side effects, flulike symptoms, thrombosis, thrombocytopenia, VITT, CLS, Guillain-Barre syndrome | 59.5–74.0% |
| Nuvaxovid | Protein subunit vaccine | above 18 years old | 2 doses, the second after 3 weeks. | local side effects, flulike symptoms | 89.7% |